[PDF][PDF] TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group
VI Gaidzik, P Paschka, D Spath, M Habdank… - J Clin Oncol, 2012 - Citeseer
VI Gaidzik, P Paschka, D Spath, M Habdank, CH Kohne, U Germing, M von Lilienfeld-Toal…
J Clin Oncol, 2012•CiteseerPurpose The tet oncogene family member 2 (TET2) gene was recently identified to be
mutated in myeloid disorders including acute myeloid leukemia (AML). To date, there is
increasing evidence for a functional role of TET2 mutations (TET2mut) in AML. Thus, we
explored the frequency, geneexpression pattern, and clinical impact of TET2mut in a large
cohort of patients with AML in the context of other AML-associated aberrations.
mutated in myeloid disorders including acute myeloid leukemia (AML). To date, there is
increasing evidence for a functional role of TET2 mutations (TET2mut) in AML. Thus, we
explored the frequency, geneexpression pattern, and clinical impact of TET2mut in a large
cohort of patients with AML in the context of other AML-associated aberrations.
Purpose
The tet oncogene family member 2 (TET2) gene was recently identified to be mutated in myeloid disorders including acute myeloid leukemia (AML). To date, there is increasing evidence for a functional role of TET2 mutations (TET2mut) in AML. Thus, we explored the frequency, geneexpression pattern, and clinical impact of TET2mut in a large cohort of patients with AML in the context of other AML-associated aberrations.
Citeseer